Swedish Orphan Biovitrum Logo

Swedish Orphan Biovitrum

SOBI | ST

Overview

Corporate Details

ISIN(s):
SE0000872095 (+51 more)
LEI:
549300124Y3MQI87PT35
Country:
Sweden
Address:
Tomtebodavagen 23A, 112 76 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Swedish Orphan Biovitrum (Sobi) is a global biopharmaceutical company dedicated to developing and delivering innovative therapies for people with rare and debilitating diseases. The company focuses its research, development, and commercialization efforts on treatments in the areas of haematology, immunology, and specialty care. Sobi leverages its expertise in protein biochemistry and biologics manufacturing to address significant unmet medical needs. The company is committed to improving patient lives by providing sustainable access to transformative treatments for rare disease communities worldwide.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Swedish Orphan Biovitrum. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-21 12:35
Share Issue/Capital Change
Sobi has completed issues of class C shares
English 151.8 KB
2025-08-21 12:35
Share Issue/Capital Change
Sobi har genomfört emissioner av C-aktier
Swedish 151.6 KB
2025-07-16 08:00
Quarterly Report
Swedish 4.1 MB
2025-07-16 08:00
Earnings Release
English 4.1 MB
2025-07-15 19:15
Share Issue/Capital Change
The Board of Directors of Sobi exercises authorisation for repurchase of shares…
English 138.4 KB
2025-07-15 19:15
Transaction in Own Shares
Sobis styrelse utnyttjar återköpsbemyndigande för säkerställande av bolagets åt…
Swedish 137.1 KB
2025-07-01 13:00
M&A Activity
Sobi uppdaterar avtalet med Apellis om royalty på Aspaveli® (systemisk pegcetac…
Swedish 193.0 KB
2025-07-01 13:00
M&A Activity
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli…
English 202.6 KB
2025-06-28 00:55
Regulatory News Service
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and…
English 227.3 KB
2025-06-28 00:55
Earnings Release
FDA godkänner Gamifant® (emapalumab-lzsg) som den första behandlingen för vuxna…
Swedish 244.4 KB
2025-05-08 11:30
Post-Annual General Meeting Information
Kommuniké från Sobis årsstämma
Swedish 148.7 KB
2025-05-08 11:30
Post-Annual General Meeting Information
Bulletin from Sobi’s Annual General Meeting (AGM)
English 158.7 KB
2025-04-29 08:00
Quarterly Report
Swedish 4.1 MB
2025-04-29 08:00
Quarterly Report
English 4.1 MB
2025-02-05 08:01
Earnings Release
Swedish 4.1 MB

Automate Your Workflow. Get a real-time feed of all Swedish Orphan Biovitrum filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Swedish Orphan Biovitrum via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-30 Katy Mazibuko Other Sell 1,500 480,000.00 SEK
2024-08-30 Katy Mazibuko Other Sell 269 86,012.75 SEK
2024-08-12 Sara Karlsson Other Buy 86 23,391.79 SEK
2024-07-25 Mahmood Ladha Other Buy 84,585 12,360,406.05 SEK
2024-07-23 Mahmood Ladha Other Sell 84,585 24,614,235.00 SEK
2024-06-10 Christin Wesström Other Other 7,433 N/A
2024-06-03 Guido Oelkers Other Buy 117,332 23,965,061.00 SEK
2024-05-30 Guido Oelkers Other Sell 117,332 32,090,302.00 SEK
2024-05-15 Henrik Stenqvist Other Buy 72,534 14,815,069.50 SEK
2024-05-13 Henrik Stenqvist Other Sell 72,534 20,766,484.20 SEK

Peer Companies

Company Country Ticker View
Vivesto Logo
Develops therapies for hard-to-treat cancers in human and veterinary oncology.
Sweden VIVE
WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo Japan 4512
Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden XBRANE
Xspray Pharma Logo
Develops improved PKI cancer drugs using patented amorphous tech for earlier market entry.
Sweden XSPRAY
Y.B Urban Renewal - Residential Development LTD Logo Israel CSURE-M
YUKI GOSEI KOGYO CO.,LTD. Logo Japan 4531
Zelluna ASA Logo
Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.
Norway ULTI
Zentiva 2 Logo
Develops and commercializes affordable generic, OTC, and biosimilar medicines for patients.
Slovakia SKF
Zentiva S.A. Logo
Develops and distributes affordable generic, OTC, and specialty medicines across Europe.
Romania SCD
ZERIA PHARMCEUTICAL CO., LTD. Logo Japan 4559